Artwork

Content provided by Physician's Weekly. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Physician's Weekly or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

HER2+ Horizons: Debates and Decisions in Metastatic Breast Cancer: Episode 1

16:14
 
Share
 

Manage episode 494434497 series 2964307
Content provided by Physician's Weekly. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Physician's Weekly or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

First-Line Therapy—Has the Standard of Care Shifted for Good?

In this episode, Dr. Sara Tolaney, of Dana-Farber Cancer Institute, discusses how DESTINY-Breast09 is redefining first-line treatment in HER2-positive metastatic breast cancer. She explores whether T-DXd plus pertuzumab should replace the long-standing THP regimen, the future role of induction-maintenance strategies, and open questions on optimal therapy duration.

Let us know what you thought of this week’s episode on Twitter: @physicianswkly

Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at [email protected]!

Thanks for listening!

  continue reading

199 episodes

Artwork
iconShare
 
Manage episode 494434497 series 2964307
Content provided by Physician's Weekly. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Physician's Weekly or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

First-Line Therapy—Has the Standard of Care Shifted for Good?

In this episode, Dr. Sara Tolaney, of Dana-Farber Cancer Institute, discusses how DESTINY-Breast09 is redefining first-line treatment in HER2-positive metastatic breast cancer. She explores whether T-DXd plus pertuzumab should replace the long-standing THP regimen, the future role of induction-maintenance strategies, and open questions on optimal therapy duration.

Let us know what you thought of this week’s episode on Twitter: @physicianswkly

Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at [email protected]!

Thanks for listening!

  continue reading

199 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play